Mr. Todd Shapiro reports

RED LIGHT HOLLAND'S WHOLLY OWNED SUBSIDIARY, FILAMENT HEALTH, SIGNS AGREEMENT TO SUPPLY PEX010 BOTANICAL PSILOCYBIN DRUG CANDIDATE FOR STUDY AT GHU PARIS PSYCHIATRIE & NEUROSCIENCES IN FRANCE

Following the acquisition of Filament Health Corp., Red Light Holland Corp. has expanded its pharmaceutical-grade manufacturing, regulatory, and clinical research capabilities, supporting the advancement of naturally derived psilocybin development and Filament's patented botanical drug candidate, PEX010.

The company is pleased to announce that Filament has signed an agreement with GHU Paris Psychiatrie & Neurosciences, a leading French university hospital group for psychiatry and neuroscience, to supply PEX010 in support of an academic clinical study titled "Ketapsychecog: effects of ketamine and psilocybin on behavioral and neural measures: a randomized, double blinded, cross-over study in healthy volunteers."

The study is a randomized, double-blinded, cross-over trial in healthy volunteers designed to compare the behavioural and neural effects of psilocybin and ketamine. PEX010 will be supplied for the psilocybin component of the study. Mechanistic research of this kind, conducted in healthy volunteers, complements the patient population trials within the network by helping to characterize how naturally derived psilocybin acts on the brain.

The agreement adds France to Filament's expanding international clinical research footprint and reflects Red Light's continued commitment to supporting independent research with good-manufacturing-practice-compliant, standardized, naturally derived psilocybin. As academic and clinical interest in psilocybin continues to grow across new jurisdictions, the company believes that a quality-controlled and regulatory-conscious supply framework will be an increasingly important factor in how this research is conducted and ultimately translated into care.

PEX010 is Filament Health's patented botanical psilocybin drug candidate and is currently supplied to more than 80 studies worldwide, making it one of the most widely studied botanical psilocybin drug candidates in regulated clinical research.

About Red Light Holland Corp.

Red Light is an Ontario-based organization advancing a focused strategy within the legal psychedelic sector, centred on consensual data collection and research and development initiatives designed to expand naturally occurring drug development and understanding of psilocybin use and consumer experiences. In parallel, the company operates commercial activities across Europe and North America, including psilocybin truffle sales in the Dutch legal market and mushroom home grow kits offered through business-to-business and direct-to-consumer channels, in compliance with applicable laws.

About Filament Health Corp.

Filament Health is a clinical-stage natural psychedelic drug development company. Filament believes that safe, standardized, naturally derived psychedelic medicines can improve the lives of many, and its mission is to see them in the hands of everyone who needs them as soon as possible. Filament's platform of proprietary intellectual property enables the discovery, development and delivery of natural psychedelic medicines for clinical development. Filament is paving the way with the first ever natural psychedelic drug candidates.

We seek Safe Harbor.